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LETTERS TO THE EDITOR
Superﬁcial acral ﬁbromyxoma on 
the tip of the big toe: expression 
of CD10 and nestin
Editor
Superﬁcial acral ﬁbromyxoma is a rare, distinctive soft
tissue benign neoplasm that has a predilection to develop
on the hands and feet of adults. Except for the only rare
location on the palm, superﬁcial acral ﬁbromyxoma
usually involves the ﬁngers and toes, and the big toe tends
to be the most frequently affected site.1–6 Most cases of
superﬁcial acral ﬁbromyxoma tend to occur in either the
subungal or periungal regions, although only two rare
cases occurring on the ventral surface of the digit have
been previously described.1,5 We herein report a case of
superﬁcial acral ﬁbromyxoma, which developed at the
most common site (i.e. the big toe), but it occurred in a
rare region of this toe (i.e. on the tip of the toe).
A 53-year-old healthy man presented with an asymp-
tomatic, slowly growing nodule with a 3-year history
on the tip of his right big toe. Examinations revealed a
hemisphere-shaped, slightly reddish nodule, measuring
1.0 cm × 0.8 cm × 0.7 cm in size, on the tip of his right big
toe (ﬁg. 1a). Neither the involvement of the ungal region
by the lesion nor any deformity of the nail plate was
seen. Computed tomography scanning as well as plane
radiographs revealed no involvement of the bone and
no bone alterations. The nodule was completely excised,
and a V-Y local advancement ﬂap was also applied to the
defect. Neither recurrence nor metastasis has been
observed in the subsequent 1-year follow-up.
Histopathologically, the excised nodule was a well-
circumscribed, globularly projecting lesion, which was
located in the whole dermis while pushing against the
subcutis (ﬁg. 1b). The lesion was composed of proliferated
spindle and stellate cells with random, loose storiform,
and fascicular patterns, which were embedded in myxoid
or myxocollagenous stroma (ﬁg. 2a,b). The proliferating
cells showed no nuclear atypia, and strands of cells with
wavy nuclei were sometimes seen. The accentuated
vasculature and some inﬂammatory cells, composed of
mast cells and lymphocytes, were also involved within the
lesion. Alcian blue staining revealed abundant mucinous
material within the stroma. Immunohistochemical study
revealed that most of the neoplastic cells (> 80%) were
positive for CD34, CD99, CD10, and Vimentin (ﬁg. 2c),
and they were negative for S-100 protein, epithelial
membrane antigen. Factor XIIIa labelled only scattered
dendritic cells within the lesion. Nestin was positive for
about 30% of the neoplastic cells, mainly in myxoid area
(ﬁg. 2d). The histopathological and immunohistochemical
features in the presented case closely corresponded to
those of superﬁcial acral ﬁbromyxoma.
From a clinical point of view, the important points in
superﬁcial acral ﬁbromyxoma are as follows: (i) a frequent
deformity of the nail plate,1–6 (ii) a usual need for the
removal of the nail plate during surgical procedures,3,6
and (iii) a rare deformity of the bone,1,6 because most cases
of this condition affect either the subungal or periungal
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ﬁg. 1 (a) A hemisphere-shaped, slightly reddish nodule on the tip of the patient’s right big toe. (b) A scanning magniﬁcation, which was photographed
directly to a slide using a special camera, showing a well-circumscribed, globularly projecting lesion to be located in the whole dermis while pushing against
the subcutis (haematoxylin and eosin, ×1.5).Letters to the Editor
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regions. Owing to its rare location (i.e. the tip of the toe),
the case presented herein showed no deformity of either
the nail plate or bone, and this lesion could therefore be
completely excised without the need to remove the nail
plate.
The histogenesis of superﬁcial acral ﬁbromyxoma is still
unclear. Within the skin, the expression of CD10 has been
reported in normal mesenchymal cells in the nail unit.7
Recent investigations have revealed that multipotent pre-
cursors isolated from the dermis, which can differentiate
into both neural and mesodermal progeny, also express
nestin.8–10 Therefore, the presented case may suggest that
the neoplastic cells in this condition are related to the
mesenchymal cells in the nail unit (onychoblasts) and
show dedifferentiation into or include multipotent dermal
stem cells.
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ﬁg. 2 (a) The proliferated spindle and stellate
cells with random and fascicular patterns in the
myxoid stroma. (b) Those proliferated cells in the
myxocollagenous stroma. (c) CD10 show positive
staining in most of the neoplastic cells. (d) Nestin
is positive for about 30% of the neoplastic cells
mainly in the myxoid area. Note the labelling of
nestin also in the endothelial cells of the capillaries
and small vessels within the lesion. (haematoxylin
and eosin: a, b ×50; Immunostain: c, d ×60).Letters to the Editor
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Inﬂiximab for patients with plaque 
psoriasis and severe psychiatric 
comorbidity
Editor
Psoriasis, a common genetically determined inﬂammatory
skin disease, is in many patients associated with psychiatric
morbidity,1 especially depression and suicidal tendencies.2
Because psychological distress has a detrimental effect on
treatment outcome,3 patients with overt psychiatric morbidity
are usually excluded from therapeutic trials for psoriasis.
Recently, it has been reported that inﬂiximab, a chimerical
anti-tumour necrosis factor-α (TNF-α) antibody, is an
effective treatment for moderate-to-severe plaque psoriasis.4
Here, we report on the treatment of three patients
comorbid for severe psoriasis and psychiatric disturbances
with inﬂiximab (Remicade®, 5  mg/kg body weight
intravenously (i.v.) at weeks 0, 2, and 6 and every 8 weeks
thereafter).
Patient 1
Male, 21  years old, with psoriasis [Psoriasis Area and
Severity Index (PASI), 20] not adequately treated for
bipolar disorder (ICD-10 F.31) with olanzapine 15 mg/day.
Anti-psoriatic treatment continues for 12 months; PASI
improved substantially (95%); and also symptoms of
bipolar disorder seem to be stabilized.
Patient 2
Female, 49  years old, with psoriasis (PASI, 8.7) and
recurrent depression with psychotic symptoms (ICD-10
F.33.3), under treatment with venlafaxine (300 mg/day) and
olanzapine (10 mg/day), continues anti-psoriatic treatment
for 10  months. PASI improved by 75%, and residual
symptoms of depression have been also improved.
Patient 3
Male, 47 years old, with severe psoriasis (PASI, 25) and
bipolar disorder (ICD-10 F.31) with borderline personality
traits, inadequately treated due to compliance problems
with risperidone (5 mg/day), lithium carbonate (blood levels:
0.69 mEq/L), and venlafaxine (150 mg/day). Anti-psoriatic
treatment was initiated; however, the patient interrupted
it after the second infusion, whereas psoriasis begun
remitting. Nine months later (PASI, 28), on the occasion
of an admission to the psychiatric clinic, inﬂiximab
was restarted with signiﬁcant psoriasis improvement
(PASI improvement 55% after 3 months) and continued
psychiatric treatment adherence meanwhile for 4 months.
As these cases indicate, treatment with inﬂiximab
was generally well tolerated, and psoriasis improved in
relation to the degree of treatment adherence. Moreover, in
all three psoriasis patients with overt psychiatric morbidity,
treatment with inﬂiximab resulted to signiﬁcant stabiliza-
tion or even improvement of the manifestations of their
affective disorders. Although compliance still remains the
critical point in the treatment of psoriatics with psychiatric
comorbidity, inﬂiximab for many reasons seems to be a
promising treatment alternative for this group of patients:
(i) it is a physician-adhered and physician-controlled,
easy-to-perform treatment modality with acceptable
compliance and excellent control of side-effects; (ii) the i.v.
application route is generally well accepted by psychiatric
patients; (iii) increased serum concentrations of pro-
inﬂammatory cytokines, such as TNF-α, are recently
associated with major depression as well as with both